Phase III and pivotal trial results — positive and negative, treated alike.
Roche's T-cell engager Lunsumio met its primary endpoint in a phase 3 confirmatory trial in earlier-line follicular lymphoma, adding another milestone for the company's T-cell engager portfolio.
Why it matters: Phase 3 confirmatory trial met its primary endpoint in follicular lymphoma.
Chia Tai Tianqing's HER2 bispecific ADC TQB2102 has hit its prespecified primary endpoint and key secondary endpoints in the Phase III TQB2102-III-01 trial, per an interim analysis judged by an independent data monitoring committee. The trial tested the drug in HER2-low recurrent or metastatic breast cancer. The company says TQB2102 balances efficacy and safety through three core technical features.
Why it matters: Positive interim readout in Phase III moves a domestic HER2-low breast cancer ADC closer to approval.
The B7-H3-targeted antibody-drug conjugate Tam-Peli reduced the risk of death by 54% in patients with small cell lung cancer, according to findings presented at this year's World Conference on Lung Cancer. Tam-Peli is one of two B7-H3-directed ADCs for small cell lung cancer highlighted at the meeting, a cancer described as highly malignant, rapidly progressing and limited in treatment options.
Why it matters: A 54% death-risk reduction in small cell lung cancer, where treatment options are few.
Longeveron's phase 2b trial of its stem cell therapy for a pediatric heart disease missed its primary endpoint. The company promptly announced cost cuts and said it would "evaluate all options" amid tight funding.
Why it matters: Phase 2b miss in pediatric heart disease triggered cost cuts and strategic review.
At the 2026 ESC Congress, HighTide Therapeutics' oral AMPK-NLRP3 dual-mechanism drug HTD1801 showed multi-organ effects across cardiovascular-kidney-metabolic (CKM) disease. In two phase 3 trials in type 2 diabetes it met primary endpoints, with HbA1c changes of -1.3% and -1.2% at week 24, sustained to week 52. It also lowered LDL-C and non-HDL-C, and in a glomerular hyperfiltration subgroup reduced the eGFR slope by 3.00 mL/min/1.73 m2 per year versus placebo.
Why it matters: Phase 3 and ESC data show one oral drug improving glycemic, lipid and eGFR outcomes across CKM syndrome.
LLM judges match clinician ratings for safety screening and factual verification of patient communication about trial informed consent (Spearman ρ > 0.80), but agree less on communication quality (ρ < 0.60). Using a seven-criterion rubric validated on ICON-Bench, 19 LLM judges were benchmarked; safety-specialized guard models underperformed general-purpose models, and patient advocates rated communication quality lower than both clinicians and LLM judges. The results support LLM judges for scalable oversight, with recalibration needed to patient-centered standards.
Why it matters: It quantifies where LLM judges can and cannot replace clinician review of patient-facing communication.
Phase 3 data for Vera Therapeutics' Trutakna show the drug stabilizes kidney function in patients with IgA nephropathy, consistent with the earlier clinical success of Otsuka's Voyxact, intensifying competition in the IgAN treatment field.
Why it matters: Phase 3 success for Trutakna intensifies competition in the IgAN market.
Novartis has discontinued an amyotrophic lateral sclerosis (ALS) program after a phase 2 trial failure, adding another setback to its recently troubled R&D pipeline. The drug's code name and trial details were not disclosed.
Why it matters: Phase 2 failure ends Novartis ALS program, extending R&D losses.
A single-center retrospective study of 454 colorectal endoscopic submucosal dissection (ESD) procedures found that a non-anesthesiologist-administered propofol (NAAP) regimen was feasible in patients of all ages, with no procedure discontinuation, intubation, anesthesiologist rescue, or death due to sedation-related adverse events.
Why it matters: Single-center study reports feasibility of non-anesthesiologist-administered propofol across all age groups.
Phase I results for GenFleet's oral KRAS G12D inhibitor GFH375 in advanced solid tumors were published in Nature Medicine. Across 100–900 mg once-daily doses, the drug showed encouraging antitumor activity and manageable safety in heavily pretreated patients with pancreatic cancer and NSCLC.
Why it matters: Phase I data published in Nature Medicine support registration studies across multiple tumor types.
Ivonescimab, a PD-1/VEGF bispecific antibody, beat Merck's Keytruda on overall survival in the HARMONi-2 study, a phase III head-to-head trial in advanced NSCLC, with median OS of 30.8 months versus 22.6 months and a 27% reduction in relative risk of death. This is the first time a PD-1/VEGF bispecific has defeated Keytruda on overall survival in a phase III head-to-head trial. Akeso and Summit Therapeutics presented the data at the World Conference on Lung Cancer.
Why it matters: First phase III head-to-head overall survival win over Keytruda by a PD-1/VEGF bispecific in advanced NSCLC.
Ivonescimab, a PD-1/VEGF bispecific antibody from Akeso, has delivered full overall survival results from the phase 3 HARMONi-2 trial, with a median OS of 30.8 months versus 22.6 months for pembrolizumab monotherapy in a head-to-head comparison. Reported by Caicun Zhou of Shanghai East Hospital, this makes ivonescimab the first cancer immunotherapy to achieve positive results in both progression-free survival and overall survival against pembrolizumab in a randomized, double-blind phase 3 study. A key regulatory decision point arrives in November.
Why it matters: First randomized double-blind phase 3 trial to beat pembrolizumab head-to-head on both PFS and OS.
In the first clinical study of HRS-4642 combined with adebrelimab in previously treated patients with metastatic KRAS G12D-mutant pancreatic cancer, the chemotherapy-free regimen showed manageable safety and preliminary antitumor activity.
Why it matters: First clinical study of a chemotherapy-free combination in this patient population.
Final two-year Phase 3 results show Trutakna, Vera Therapeutics' drug for IgA nephropathy, stabilized kidney function and reduced the risk of kidney-related death and other complications. The FDA granted Trutakna accelerated approval for IgAN in July, and Vera plans to file for full approval in the fourth quarter.
Why it matters: Final Phase 3 data support converting Trutakna's accelerated approval into full FDA approval for IgA nephropathy.
The oral dual on-off binding KRAS G12D inhibitor GFH375 was evaluated in a phase 1 trial in patients with previously treated KRASG12D-mutated advanced solid tumors. Most treatment-related adverse events were low-grade, but there was one treatment-related death. Response rates were described as encouraging in non-small cell lung cancer and pancreatic cancer.
Why it matters: First-in-human phase 1 data on an oral KRAS G12D inhibitor across KRASG12D-mutated solid tumors.
In the phase 2 RIO trial, adult males living with HIV undergoing analytical treatment interruption showed delayed viral rebound after receiving broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS, with resistance to these antibodies also observed. Initial reservoir sensitivity to autologous antibodies was associated with a longer time to rebound. The findings come from secondary and exploratory outcomes of this randomized controlled trial.
Why it matters: Antibody-based delay of viral rebound and a predictor of longer rebound time inform HIV treatment-interruption strategies.
Gotistobart, a next-generation CTLA-4 antibody from BioNTech and OncoC4, nearly doubled median overall survival in previously treated squamous non-small cell lung cancer in updated stage 1 data from the phase 3 PRESERVE-003 trial. Median overall survival was 18.5 months with gotistobart versus 10.0 months with standard-of-care chemotherapy. The data support its mechanism of selectively depleting regulatory T cells in the tumor microenvironment.
Why it matters: Phase 3 data show a near-doubling of median overall survival with gotistobart monotherapy in previously treated squamous NSCLC.
GFH375 monotherapy at 600 mg once daily produced an objective response rate of 59.2% and a confirmed objective response rate of 52.1% in previously treated KRAS G12D-mutant non-small cell lung cancer, with a disease control rate of 93% among 71 evaluable patients. Nearly all enrolled patients had distant metastases and over 40% had received two or more prior lines. The updated phase 2 data were presented in an oral report at the 2026 World Conference on Lung Cancer in Seoul.
Why it matters: Phase 2 efficacy data for a KRAS G12D inhibitor in heavily pretreated NSCLC, selected for oral presentation at WCLC 2026.
AstraZeneca's camizestrant missed its primary endpoint of progression-free survival in the Phase III SERENA-4 trial in first-line HER2-negative, estrogen receptor-positive breast cancer, where it was combined with the CDK4/6 inhibitor palbociclib. This is the second Phase III setback this year for oral SERDs in an early-line breast cancer setting, and both results suggest proving efficacy may require focusing on patients with ESR1 mutations.
Why it matters: A second Phase III oral SERD failure narrows where the class can compete and points to ESR1-mutant selection.
Definium Therapeutics' LSD therapy DT120 reduced anxiety in a second late-stage trial, positioning the company to seek the first approval of a psychedelic drug for anxiety. Over 12 weeks, patients on a 100-microgram dose had a 9.8-point drop on the Hamilton Anxiety Rating Scale versus 4.7 points on placebo, a 5.1-point difference matching the first late-stage study, with changes seen as early as the second day after dosing.
Why it matters: Second positive pivotal trial sets up the first regulatory approval of a psychedelic drug for anxiety.
